<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153229</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 14513</org_study_id>
    <nct_id>NCT02153229</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma</brief_title>
  <acronym>MPM-PDT</acronym>
  <official_title>A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated&#xD;
      photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the&#xD;
      treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given&#xD;
      the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking.&#xD;
      Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic&#xD;
      light dosimetry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival months</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival months</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Control</measure>
    <time_frame>4 years</time_frame>
    <description>progression with death as a competing risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receipt of Pembrolizumab</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Epitheliod Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>patients who undergo RP plus photofrin-based PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients who undergo RP alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photodynamic Therapy</intervention_name>
    <arm_group_label>patients who undergo RP plus photofrin-based PDT</arm_group_label>
    <other_name>PDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical Pleurectomy</intervention_name>
    <arm_group_label>patients who undergo RP alone</arm_group_label>
    <arm_group_label>patients who undergo RP plus photofrin-based PDT</arm_group_label>
    <other_name>RP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <arm_group_label>patients who undergo RP alone</arm_group_label>
    <arm_group_label>patients who undergo RP plus photofrin-based PDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photofrin 2.0 mg/kg</intervention_name>
    <description>If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy</description>
    <arm_group_label>patients who undergo RP plus photofrin-based PDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion&#xD;
             of the attending thoracic surgeon can receive a macroscopically complete resection of&#xD;
             tumor.&#xD;
&#xD;
          -  Patients must have disease limited to the hemithorax.&#xD;
&#xD;
          -  Patients who have received prior surgery, gene therapy, or combination chemotherapy&#xD;
             will be permitted if it has been at least 30 days since the last treatment.&#xD;
&#xD;
          -  Subjects treated with pemetrexed previously will be eligible only if 30 days have&#xD;
             elapsed between the last dose of pemetrexed and the date of surgery.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Medical suitability for resection, including documented medical and cardiac clearance.&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Patients must sign a document that indicates that they are aware of the investigative&#xD;
             nature of the treatment of this protocol, and the potential benefits and risks.&#xD;
             Patients unwilling or unable due to cognitive impairment to sign informed consent are&#xD;
             excluded from the study.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Patients with active invasive cancers, other than MPM, that require additional&#xD;
             treatment, except non-melanomatous skin cancer, superficial bladder or cervical&#xD;
             cancer, and early-stage prostate cancer&#xD;
&#xD;
          -  Pregnant or lactating patients.&#xD;
&#xD;
          -  Patients who have a history of HIV disease.&#xD;
&#xD;
          -  Patients who have a white count less than 2,500 per cubic mm or platelets less than&#xD;
             100,000/cubic mm.&#xD;
&#xD;
          -  Serum creatinine equal or greater than 2.5 mg/deciliter.&#xD;
&#xD;
          -  Patients who have severe liver disease including cirrhosis, Grade III-IV elevations in&#xD;
             liver function studies, or bilirubin in excess of 1.5 mg/deciliter.&#xD;
&#xD;
          -  Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.&#xD;
&#xD;
          -  Patients who have been treated with pemetrexed if the last dose of pemetrexed is &lt; 30&#xD;
             days to the date of surgery.&#xD;
&#xD;
          -  Patients that have been treated with prior Mantle field radiation.&#xD;
&#xD;
          -  Patients with distant metastatic disease or otherwise not confined to the ipsilateral&#xD;
             hemithorax.&#xD;
&#xD;
          -  Subjects who have received more than 2 doses of neo-adjuvant chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Cengel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally McNulty, RN</last_name>
    <phone>215-662-7720</phone>
    <email>Sally.Mcnulty@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rosewell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Dunn, MPH, CCRP</last_name>
      <phone>716-845-1300</phone>
      <phone_ext>6537</phone_ext>
      <email>kelly.dunn@roswellpark.org</email>
    </contact>
    <contact_backup>
      <last_name>Elongia Farrell, BA, CCRC</last_name>
      <phone>716-845-3114</phone>
      <email>elongia.farrell@roswellpark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sai Yendamuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally McNulty, RN</last_name>
      <phone>215-662-7720</phone>
      <email>Sally.McNulty@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keith Cengel, MD, PhD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact_backup>
    <investigator>
      <last_name>Keith Cengel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Histological diagnosis of MPM</keyword>
  <keyword>epitheliod subtype</keyword>
  <keyword>limited to the hemithorax</keyword>
  <keyword>macroscopically complete resection of the tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

